Comprehensive Study by AstraZeneca and Genentech Confirms Superiority of InSphero Human Liver Microtissues for Prediction of Drug-Induced Liver Injury
InSphero AG / Comprehensive Study by AstraZeneca and Genentech Confirms Superiority of InSphero Human Liver Microtissues for Prediction of Drug-Induced Liver Injury . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Archives of Toxicology publication reveals microtissues are twice as sensitive as 2D primary human hepatocytes (PHH) for predicting hepatotoxicity of 110 clinically defined DILI compounds.
Schlieren, Switzerland, June 29, 2017 (GLOBE NEWSWIRE) -- In the most comprehensive evaluation of 3D spheroid hepatic cultures conducted to date, a publication co-authored by lead toxicologists and drug safety experts at AstraZeneca and Genentech revealed InSphero 3D InSight(TM) Human Liver Microtissues to be a more sensitive and highly specific in vitromodel for predicting drug-induced liver injury (DILI) compared to 2D models. The study entitled, "Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury," was published online Tuesday, June 13 in the journal Archives of Toxicology. Dr. William Proctor, Head of Investigative Toxicology at Genentech, and Alison Foster, Senior Scientist in the Drug Safety and Metabolism group at AstraZeneca, were co-first authors on the publication.
2D PHH assays have been the "gold-standard" model used for DILI testing, yet DILI still remains one of the leading sources for drug attrition, black box warnings, and post-market withdrawal of drugs. Thus, there is a growing need for better predictive tools to assess liver injury earlier in the drug development process. The authors note in the paper that, "3D models have shown promise in small sets of DILI compounds, but a more comprehensive retrospective study of DILI positive and negative drugs to test the predictive power of 3D models head to head with 2D PHH assays had not been performed."
The study determined that regardless of the threshold used, "Human Liver Microtissues demonstrated increased sensitivity in identifying known hepatotoxicants versus PHH, while specificity was consistent across both assays." Microtissues also, "outperformed PHH in correctly classifying hepatotoxicants from different pharmacological classes of molecules." Furthermore, the authors found that 3D microtissues displayed sufficient structural and functional characteristics to warrant exploratory studies to see if novel biomarkers used in the clinic could also be detected in vitro. Findings revealed that despite each microtissue consisting of ~1000 cells, the mechanistic and exploratory hepatotoxicity biomarkers miR-122, HMGB1, and alpha-GST could be detected in the culture supernatants, demonstrating that, "3D liver microtissues have the potential to recapitulate in vivo findings in vitro."
"This landmark study provides convincing, independent evidence that InSphero liver microtissues can help identify hepatotoxic drugs with greater sensitivity without sacrificing specificity, says InSphero Chief Executive Officer and Co-founder Dr. Jan Lichtenberg. "Having two of the world's leading pharmaceutical companies collaborate to produce this thorough validation further confirms that our 3D models not only better reflect in vivo biology, but also deliver the reproducibility and scalability required to meet the early stage screening demands of large pharma. Our assay-ready 3D InSight(TM) models offer a cost-effective, turnkey solution that gives toxicologists greater confidence when characterizing risk in lead compound sets."
3D InSight(TM) Human Liver Microtissues are a standardized primary human liver model developed by InSphero that display enhanced liver phenotype, metabolic activity, and stability over 28 days in culture, enabling long-term drug exposure studies not attainable with 2D hepatic models.
For more information about InSphero 3D InSight(TM) Liver Microtissues and applications, visit www.insphero.com
InSphero sets the standard for in vitro testing of novel drugs in the pharmaceutical and biotechnology industry with comprehensive solutions that provide greater confidence in decision making. Its robust and highly physiologically relevant suite of 3D InSight(TM) Microtissues and Services are used by major pharmaceutical companies worldwide to increase efficiency in drug discovery and safety testing. InSphero patent-pending technologies and methods enable large-scale, reproducible production of scaffold-free 3D microtissues driven solely by cellular self-assembly. The company specializes in delivering assay-ready and custom 3D models derived from liver, pancreas, and tumor tissues, to provide unrivalled biological insight into liver toxicology, metabolic diseases (e.g., diabetes and liver diseases), and oncology (with a focus on immuno-oncology). All InSphero microtissues are thoroughly validated to ensure the highest quality, certified for use in a variety of assays, and shipped globally to customers in a patented, easy-to-use spheroid-optimized platform, ready for research. Field application scientists and research staff with expertise in working with 3D models help ensure efficient integration and onsite training as needed. For customers who prefer an outsourcing strategy with fast turnaround, InSphero also offers contract research services utilizing their 3D microtissue models.
InSphero 3D InSight(TM) solutions drive significant findings in peer-reviewed journals, through collaborative industry initiatives such as EU-ToxRisk and HeCaToS, and have gained validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies.
Founded in 2009, the privately held company is headquartered in Switzerland, with subsidiaries in the United States and Germany. It has been recognized for its scientific and commercial achievements with several national and international awards.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/49b63be5-b99c-4789-82ec-255febd1bef4
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/cd947eeb-93b5-4005-9072-76223d78942a
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/6f21ed8c-d6f6-4bd2-bf0e-f6e0e46ea6ff
+41 44 515 0490
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: InSphero AG via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
BBVA Continental: the bank making waves in Peru24.1.2018 12:31 | Pressemelding
LONDON, Jan. 24, 2018 (GLOBE NEWSWIRE) -- BBVA Continental has picked up the 2017 award for 'Best Private Bank - Peru' in World Finance magazine's yearly line-up, which recognises those in the industry that are outperforming the rest and making astute business decisions in preparation for future trends. BBVA continental is the second largest bank in Peru, but is number one when it comes to the cost of risk, coverage ratio and non-performing loan ratio. It is currently seeing outstanding growth, with a year-on-year increase in performing loans of 2 percent and a 6.1 percent year-on-year increase in deposits. It has also invested heavily in a transformative digital strategy, thereby laying the foundations for further expansion in the future. A remarkable shift in the way that people carry out transactions illustrates the success of its transition towards digital platforms. In 2008, internet banking comprised just 18 percent of its transactions, but the latest results show that this has n
Block X Capital Corp. Announces Completion of Change of Business to Investment Issuer, Change of Name, Change of Management and Resumption of Trading24.1.2018 11:00 | Pressemelding
VANCOUVER, British Columbia, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Block X Capital Corp. ("Block X" or the "Company") (CSE:BXXX) is pleased to announce that further to its press release on December 7, 2017, the Company has completed a change of business from a Mining Issuer to an Investment Issuer and has received approval from the Canadian Securities Exchange to resume trading. In connection with the change of business, the Company has changed its name to "Block X Capital Corp.". Trading of the Company's common shares will resume under the new name and under the new ticker symbol "BXXX" at market open on January 24, 2018. The Company will seek investment opportunities in early-stage to mid-level blockchain and emerging technology companies, and will leverage its extensive network of operators and global thought leaders to provide investors with unparalleled access to investments that are not normally accessible to the average retail investor. The Company is pleased to announce that it has
Dog Meat Free Indonesia : Sickening animal cruelty at Indonesia's "extreme" markets where dogs and cats are bludgeoned, blowtorched alive24.1.2018 09:30 | Pressemelding
Government urged to take immediate action to protect animals and public health LONDON, Jan. 24, 2018 (GLOBE NEWSWIRE) -- The Indonesian government is being urged to shut down the country's cruel live animal markets, where thousands of dogs and cats a week are bludgeoned in public, blowtorched whilst still alive, and butchered for eating. Campaigners from the Dog Meat-Free Indonesia coalition filmed at two of the most notorious of Indonesia's 200 live animal markets in North Sulawesi, "Tomohon Extreme Market" and Langowan Market, to expose the horrifying suffering routinely endured by animals. Live dogs and cats are seen trembling in cages as one by one they are beaten over the head, howling in pain. Lola Webber, Dog Meat-Free Indonesia campaign coordinator, said: " It was like walking through hell. The dogs huddled together in cages , trembling with fear as they watched others being killed around them , waiting their turn. The sight of absolute terror in their eyes, the thumping of the
Promethean Expands Educational Display Portfolio to Create Immersive Classroom Experiences24.1.2018 09:18 | Pressemelding
Seattle, Wash., Jan. 24, 2018 (GLOBE NEWSWIRE) -- Promethean TM, a global education technology company, announced expansions to its interactive flat panel portfolio which includes the market-leading ActivPanel and ActivPanel i-Series. The ActivPanel continues to offer the industry's most natural writing experience using InGlassTM technology, enabling both teachers and students to collaborate in front of the class with ease. The ActivPanel i-Series is an essential interactive flat panel for customers looking to replace their projector-based systems with a long-term, reliable solution. "Educators want technology that works as they do - flexible and able to adapt to their teaching styles in any classroom setting," said Ravi Angadi, Chief Products and Strategy Officer, Promethean. "At Promethean, we strive to create a dynamic ecosystem to enhance teacher productivity, providing educators with the latest innovative education technologies that are intuitive and immersive. With access to an e
Leading Medical Organizations Update Guideline for Molecular Testing and Targeted Therapies in Lung Cancer23.1.2018 21:11 | Pressemelding
DENVER, Jan. 23, 2018 (GLOBE NEWSWIRE) -- Rapid advancements in the molecular diagnostic testing of lung cancer have led to new treatments and greater hope for patients battling lung cancer, the most common cause of cancer death worldwide. To ensure that clinicians stay apace and provide optimal patient care, three leading medical societies-the College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP)-have updated their 2013 evidence-based guideline. Published today in early online release, the "Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors," continues to set standards for the molecular analysis of lung cancers for test results that effectively guide targeted therapy and treatment. Targeted cancer therapies are drugs or other treatments that block the spread of cancer by interfering with specific molec
CashBet Seeks $40 Million for World's Only Complete Crypto-Ready Mobile iGaming Platform23.1.2018 16:31 | Pressemelding
Gaming and cryptocurrency industry leaders develop blockchain-based iGaming platform improving trust, speed, access, costs, and content availability OAKLAND, Calif., Jan. 23, 2018 (GLOBE NEWSWIRE) -- Leading mobile-first iGaming platform provider CashBet (https://coin.cashbet.com/) today announced it seeks to raise $40 million through an Initial Coin Offering (ICO) to develop the world's first complete crypto-ready mobile iGaming platform. Interactive gaming, which includes real money, social, skill-based, esports and sports betting, hit $91 billion in 2016, led by mobile gaming. Despite strong growth, current iGaming operations continue to face three major issues: trust, speed, and cost. CashBet is the first and only vertically integrated iGaming solution to leverage blockchain technology for transparent operations, increased speed, and lower transaction fees. The CashBet Coin will be available in pre-sale starting January 24, 2018 at 5:00 p.m. GMT, with a 20 percent discount offered.
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom